Speakers 2021
-
INTRODUCTION (chairman)
-
CONCLUSION (chairman)
Presentation
-
ALTER Harvey
USA
-
MEETING WITH THE 2020 NOBEL LAUREATES
Presentation
-
-
New advances in liver disease care
-
HEPATITIS DELTA (chairman)
-
New drugs for HDV
-
Hepatitis Delta: What the future holds ?
-
The present state of hepatitis Delta: epidemiology, diagnosis, and current treatments
Presentation
-
-
Hépatite C:
Presentation
-
-
The COVID-19, NASH and other liver diseases: lessons learned
-
MEETING WITH THE 2020 NOBEL LAUREATES
Presentation
-
-
Optimal management of cholangiocarcinoma
Presentation
-
-
AVANCEES DANS LE TRAITEMENT (chairman)
Presentation
-
-
INTRODUCTION (chairman)
-
INTRODUCTION (chairman)
-
AVANCEES DANS LE DIAGNOSTIC ET LE PRONOSTIC (chairman)
-
CONCLUSION (chairman)
-
IS ELIMINATION OF HCV BY 2030 REALISTIC (chairman)
-
TAKE HOME MESSAGES (chairman)
-
Immunotherapy combination: the revolution in unresectable HCC
-
INTRODUCTION (chairman)
-
LESSONS FROM COVID-19 (chairman)
-
Welcome and Introduction
-
Simplified, decentralized care - how do DAAs make this feasible ?
-
Audience Q&A
-
INTRODUCTION (chairman)
Presentation
-
BOURSIER Jérôme
France
-
NASH: Traitement actuel
Presentation
-
BUGIANESI Elisabetta
Italy
-
Natural history of NASH and HCC
Presentation
-
-
New advances in liver disease care
-
NUC therapy: the role of TAF
Presentation
-
CABEZAS Joaquin
Spain
-
Evolving your role as an HCV specialist: from concept to practice
Presentation
-
CARDOSO Ana Carolina
Brazil
-
The hepatologists
Presentation
-
-
CONFERENCE (chairman)
-
Non-invasive markers in NAFLD
Presentation
-
CHEMIN Isabelle
France
-
En collaboration avec
Presentation
-
-
HCC: ADVANCES IN DIAGNOSIS AND PROGNOSIS (chairman)
Presentation
-
CORTEZ-PINTO Helena
Portugal
-
New insights into NASH management
Presentation
-
-
LESSONS FROM COVID-19 (chairman)
-
The impact of COVID-19 on the HCV elimination program
Presentation
-
-
LES PRINCIPAUX MESSAGES (chairman)
Presentation
-
-
AVANCEES DANS LE DIAGNOSTIC ET LE PRONOSTIC (chairman)
Presentation
-
-
Acute-on-chronic liver failure
Presentation
-
DUSHEIKO Geoffrey
UK
-
HBV cure: How and when?
Presentation
-
EDELINE Julien
France
-
Immunotherapy combination: the revolution in unresectable HCC
Presentation
-
El Ray Ahmed
Egypt
-
Egypt
Presentation
-
-
HEPATITIS B (chairman)
Presentation
-
ETZION Ohad
Israel
-
Can current research change the face of hepatitis Delta ?
Presentation
-
FAIVRE Sandrine
France
-
Immunotherapy today
Presentation
-
FLISIAK Robert
Poland
-
Central Europe
-
The lasting impact of COVID-19 on HCV care and elimination efforts
Presentation
-
-
IS ELIMINATION OF HCV BY 2030 REALISTIC (chairman)
-
TAKE HOME MESSAGES (chairman)
Presentation
-
-
The surgeon
Presentation
-
-
USA
-
Real world evidence in HCC
-
TAKE HOME MESSAGES (chairman)
Presentation
-
-
Management of hepatorenal syndrome
Presentation
-
-
New algorithm for systemic therapy
Presentation
-
-
AVANCEES DANS LE TRAITEMENT (chairman)
-
Introduction
Presentation
-
Gish Robert G.
USA
-
Other Continents
Presentation
-
GLENN Jeffrey
USA
-
Eiger BioPharmaceuticals: Developing Two Foundational Treatments for HDV
Presentation
-
HILLERET Marie-Noelle
France
-
Sharing of experience with 2 clinical cases
Presentation
-
HOUGHTON Michael
USA
-
MEETING WITH THE 2020 NOBEL LAUREATES
Presentation
-
-
Eastern Europe
Presentation
-
-
Asia
Presentation
-
-
Hepatitis Delta: What the future holds ?
-
D-LIVR patient characteristics
Presentation
-
-
The role of DAAs
Presentation
-
-
How to make NAFLD a global public health priority ?
Presentation
-
LEROY Vincent
France
-
NASH: Marqueurs non invasifs
-
Current PSC management challenges
Presentation
-
-
Hépatite B: Objectif éradication virologique
Presentation
-
LIM Seng Gee
Singapore
-
HEPATITIS B (chairman)
-
Is elimination of HBV realistic ?
Presentation
-
LOHOUES KOUACOU Marie Jeanne
Cote d'Ivoire
-
ELIMINATION DES HEPATITES ET ACCES AUX ANTIVIRAUX EN AFRIQUE (chairman)
Presentation
-
-
Hépatite B et D: Applications des nouveaux marqueurs
Presentation
-
MANNS Michael
Germany
-
NAFLD/NASH: PHYSIOPATHOLOGY, DIAGNOSIS AND OUTCOME (chairman)
Presentation
-
-
INTRODUCTION (chairman)
-
INTRODUCTION (chairman)
-
INTRODUCTION (chairman)
-
CONCLUSION (chairman)
-
INTRODUCTION (chairman)
-
CONCLUSION
-
INTRODUCTION (chairman)
-
INTRODUCTION (chairman)
-
AWARD PHC 2021 (chairman)
-
MEETING WITH THE 2020 NOBEL LAUREATES
-
CONCLUSION (chairman)
-
INTRODUCTION (chairman)
-
INTRODUCTION (chairman)
-
THE BEST POSTER PRICE (chairman)
-
CONCLUSION (chairman)
Presentation
-
-
CONFERENCE (chairman)
Presentation
-
MENUET Dominique
France
-
Pfizer interest in NASH
Presentation
-
-
The diabetologist
Presentation
-
-
END STAGE LIVER DISEASE (chairman)
Presentation
-
-
CHC: Traitement personnalisé
Presentation
-
-
NAFLD/NASH: MULTIDISCIPLINARY MANAGEMENT OF A SYSTEMIC DISEASE (chairman)
Presentation
-
NTANIOS Fady
USA
-
Pfizer interest in NASH
Presentation
-
-
Other Continents
Presentation
-
-
Is Hepatitis Delta underestimated?
Presentation
-
-
The new pathology approach
-
Pathology of NAFLD/NASH revisited (chairman)
Presentation
-
-
Latin America
Presentation
-
-
Current management of Hepatitis E
Presentation
-
-
NAFLD/NASH: PHYSIOPATHOLOGY, DIAGNOSIS AND OUTCOME (chairman)
-
Physiopathology of NAFLD and NASH
Presentation
-
-
France
-
On the road to Hepatitis C elimination : what challenges for psychiatric patients ?
Presentation
-
CHUNG Raymond
USA
-
HCC: EVOLVING CONCEPTS IN THERAPY (chairman)
Presentation
-
RICE Charles
USA
-
MEETING WITH THE 2020 NOBEL LAUREATES
Presentation
-
-
HEPATITIS DELTA (chairman)
Presentation
-
Presentation
-
-
Sharing of experience with 2 clinical cases
Presentation
-
-
HCC: EVOLVING CONCEPTS IN THERAPY (chairman)
-
Changing indications for liver transplantation
Presentation
-
-
New drugs for NASH
-
R&D : THE DRUGS PIPELINE PRESENTED BY COMPANIES (chairman)
Presentation
-
-
END STAGE LIVER DISEASE (chairman)
Presentation
-
-
Making a sustainable impact on COVID-19
-
R&D : THE DRUGS PIPELINE PRESENTED BY COMPANIES (chairman)
Presentation
-
SERFATY Lawrence
France
-
NAFLD/NASH: MULTIDISCIPLINARY MANAGEMENT OF A SYSTEMIC DISEASE (chairman)
Presentation
-
-
Hépatite B:
Presentation
-
STAMM Luisa
USA
-
Assembly Biosciences: Developing Innovative Therapeutics Targeting Chronic HBV Infection
Presentation
-
TAHIRI Mohamed
Maroc
-
La NASH: Etat des lieux en Afrique
Presentation
-
TAUB Rebecca
USA
-
Madrigal: Advancing Resmetirom in Phase 3 Trials for Non-cirrhotic NASH with Liver Fibrosis Rebecca TAUB, President of Research & Development
Presentation
-
-
The emerging issue of Hepatitis Delta in Asia
Presentation
-
-
Is encephalopathy under-estimated ?
Presentation
-
TRAN Tram
USA
-
Gilead’s Commitment to Liver disease
Presentation
-
-
INVITE D’HONNEUR: (chairman)
Presentation
-
-
CHC: Progrès de l’imagerie
-
HCC: ADVANCES IN DIAGNOSIS AND PROGNOSIS (chairman)
-
The digital and imaging
Presentation
-
-
Trans-Arterial Radioembolisation (TARE)
Presentation
-
WEDEMEYER Heiner
Germany
-
How do I treat my patients ?
Presentation
-
-
ELIMINATION DES HEPATITES ET ACCES AUX ANTIVIRAUX EN AFRIQUE (chairman)
Presentation
-
ZEUZEM Stefan
Germany
-
Western Europe
Presentation
-
ZOULIM Fabien
France
-
International review of the delta through a clinical case
-
New drugs for HBV cure
Presentation
-
-
Clinical applications of genetics in HCC
Presentation
-
